



# Samrat Pharmachem Limited

**Manufacturers & Exporters of Pharmaceutical Chemicals**

**Regd. Office & Factory**

Plot No. A2/3445, GIDC,  
Phase 4, Ankleshwar - 393002,  
Gujarat, India  
Tel: +91-7045456789 / 7046456789  
Web: www.samratpharmachem.com

CIN: L24230GJ1992PLC017820

**Corporate Office**

701/702 Business Square,  
M. A. Road, Andheri (West),  
Mumbai - 400058, India  
Tel: +91-7507534567 / 8760345678  
E: contact@samratpharmachem.in

**November 8, 2023**

To,  
**Department of Corporate Services,  
BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai - 400 001.

**Scrip Code: 530125**

Dear Sir,

**Sub: Approval of Unaudited Standalone Financial Results for the quarter and half year ended September 30, 2023**

We wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Wednesday, November 8, 2023, the Board has considered and took on record the Un-Audited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2023, which is enclosed herewith along with the Statement of Asset & Liabilities, Cash Flow Statement and the Limited Review Report of the Statutory Auditor of the Company.

The meeting of the Board of Directors of the Company commenced at 15:00 hrs and concluded at 21:00 hrs.

Kindly inform all your members.

Thanking you,

Yours faithfully,  
**For Samrat Pharmachem Limited**

**Nishant Kankaria**  
**Company Secretary & Compliance Officer**

# Samrat Pharmachem Limited

Regd Office : Plot No. A2/3445, GIDC, Phase 4, Ankleshwar - 393 002, Gujarat (Website: www.samratpharmachem.com)  
Corp Office : 701/702 Business Square, M. A. Road, Andhri (West), Mumbai - 400 058 (CIN: L24230GJ1992PLC017820)



## Statement of unaudited financial results for the quarter and half year ended September 30, 2023

(Currency : Indian Rupees in lakhs)

	Quarter ended			Half year ended		Year ended
	30-Sep-23	30-Jun-23	30-Sep-22	30-Sep-23	30-Sep-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
<b>A Continuing Operations</b>						
<b>I INCOME</b>						
a) Revenue From Operations	7,974.49	5,747.99	7,111.69	13,722.48	15,761.81	31,064.59
b) Other Income	29.95	36.44	13.90	66.39	16.98	47.77
<b>Total Income</b>	<b>8,004.44</b>	<b>5,784.43</b>	<b>7,125.59</b>	<b>13,788.87</b>	<b>15,778.79</b>	<b>31,112.36</b>
<b>II EXPENSES</b>						
a) Cost of Material Consumed	7,211.13	5,564.72	6,874.54	12,775.85	14,441.56	28,800.40
b) Purchase of Traded Goods	-	-	-	-	-	-
c) Changes in inventories	508.82	(91.35)	(821.34)	417.47	(1,234.91)	(1,013.88)
d) Employee benefits expense	50.59	49.34	43.17	99.93	84.32	187.90
e) Finance costs	13.10	21.99	21.51	35.09	44.12	123.17
f) Depreciation and amortisation expense	16.31	16.19	15.99	32.50	31.76	64.30
g) Other expenses	180.76	148.28	189.69	329.04	357.23	697.43
<b>Total expenses</b>	<b>7,980.71</b>	<b>5,709.17</b>	<b>6,323.56</b>	<b>13,689.88</b>	<b>13,724.08</b>	<b>28,859.32</b>
<b>III Profit before tax before exceptional items (I - II)</b>	<b>23.73</b>	<b>75.26</b>	<b>802.03</b>	<b>98.99</b>	<b>2,054.71</b>	<b>2,253.04</b>
<b>IV Exceptional item income</b>	-	-	-	-	-	-
<b>Profit before tax after exceptional items (III + IV)</b>	<b>23.73</b>	<b>75.26</b>	<b>802.03</b>	<b>98.99</b>	<b>2,054.71</b>	<b>2,253.04</b>
<b>VI Tax expense</b>						
a) Current tax	6.03	19.00	221.65	25.03	534.91	615.82
b) Deferred tax	36.31	(4.86)	(10.89)	31.45	(7.81)	(20.69)
c) Short / (Excess) provision for tax - prior years	0.21	0.01	-	0.22	(0.32)	(5.14)
<b>Total Tax</b>	<b>42.55</b>	<b>14.15</b>	<b>210.76</b>	<b>56.70</b>	<b>526.78</b>	<b>589.99</b>
<b>VII Profit for the year (V - VI)</b>	<b>(18.82)</b>	<b>61.11</b>	<b>591.27</b>	<b>42.29</b>	<b>1,527.93</b>	<b>1,663.05</b>
<b>VIII Other Comprehensive Income</b>						
(a) Items that will not be reclassified to profit or loss						
Remeasurement (losses) / gains on defined benefit obligations	-	-	-	-	-	-
Income tax on above credit / (charge)	-	-	-	-	-	-
<b>Total (a)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
(b) Items that will be reclassified to profit or loss						
Income tax on above credit / (charge)	-	-	-	-	-	-
<b>Total (b)</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>Total other comprehensive (loss) / income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>IX Total Comprehensive Income for the year (VII + VIII)</b>	<b>(18.82)</b>	<b>61.11</b>	<b>591.27</b>	<b>42.29</b>	<b>1,527.93</b>	<b>1,663.05</b>
<b>X Basic and diluted earnings per equity share in Rupees (Face value Rs. 10 each) *</b>	<b>(0.61)</b>	<b>1.98</b>	<b>19.14</b>	<b>1.37</b>	<b>49.45</b>	<b>53.83</b>
* Not annualised for period less than one year						

For Samrat Pharmachem Limited



*[Signature]*  
Director

## Samrat Pharmachem Limited



### Notes:

- 1 The above results were reviewed by the Audit Committee of the Board of Directors.
- 2 The above results have been taken on record by the Board of Directors at its Meeting held on Wednesday, November 08, 2023 at the Corporate Office of the Company.
- 3 The Company manufactures pharmaceutical chemicals, which is a single business segment.
- 4 The figures for the previous period have been regrouped where necessary to conform to current period's classification.

**By order of the Board of Directors  
For Samrat Pharmachem Limited**



**Rajesh Mehta  
Executive Director**

**Place: Mumbai**

**Date: November 08, 2023**

**Samrat Pharmachem Limited**  
Statement of Assets & Liabilities as at September 30, 2023



(Currency : Indian Rupees in lakhs)

Particulars	As at 30-Sep-23 (Unaudited)	As at 31-Mar-23 (Audited)
<b>ASSETS</b>		
<b>I Non Current assets</b>		
a) Property, Plant and Equipment	1,085.21	1,069.50
b) Other Intangible assets	0.71	0.75
c) Financial Assets		
i) Investments	223.41	186.39
ii) Loans	25.22	24.19
iii) Other financial assets	467.65	467.74
Deferred tax assets (net)	-	-
d) Other non-current assets	4.83	4.97
e) Income-tax receivable	47.14	-
	<b>1,854.17</b>	<b>1,753.54</b>
<b>II Current assets</b>		
a) Inventories	1,994.77	3,252.78
b) Financial Assets		
i) Investments	0.07	1.39
ii) Trade receivables	6,976.35	5,123.71
iii) Cash and cash equivalents	4.93	1,186.21
iv) Other Bank balances	31.60	2.94
v) Loans	-	-
vi) Other financial assets	0.05	1.79
c) Other current assets	187.11	292.71
	<b>9,194.88</b>	<b>9,861.53</b>
<b>Total Assets</b>	<b>11,049.05</b>	<b>11,615.07</b>
<b>EQUITY AND LIABILITIES</b>		
<b>I Equity</b>		
a) Equity Share capital	308.97	308.97
b) Other Equity	6,016.76	6,005.37
<b>Total Equity</b>	<b>6,325.73</b>	<b>6,314.34</b>
<b>II LIABILITIES</b>		
<b>A Non-current liabilities</b>		
a) Financial Liabilities		
i) Borrowings	-	-
ii) Trade payables	-	-
Total outstanding dues of micro and small enterprises	-	-
Total outstanding dues of creditors other than micro and small enterprises	-	-
iii) Others	-	-
b) Provisions	-	-
c) Deferred tax liabilities (Net)	56.87	25.41
d) Other non-current liabilities	-	-
	<b>56.87</b>	<b>25.41</b>
<b>B Current liabilities</b>		
a) Financial Liabilities		
i) Short term Borrowings	2,002.79	1,865.93
ii) Trade payables		
Total outstanding dues of micro and small enterprises	-	-
Total outstanding dues of creditors other than micro and small enterprises	2,523.99	3,188.00
iii) Others	133.67	7.87
b) Provisions	-	-
c) Current Tax Liabilities (Net)	6.00	213.52
d) Other current liabilities	-	-
	<b>4,666.45</b>	<b>5,275.32</b>
<b>Total Equity and Liabilities</b>	<b>11,049.05</b>	<b>11,615.07</b>

For Samrat Pharmachem Limited



*[Signature]*  
Director

**Samrat Pharmachem Limited**  
Statement of cash flow



(Currency : Indian Rupees in lakhs)

Particulars	Half year ended 30-Sep-23 (Unaudited)	Half year ended 30-Sep-22 (Unaudited)
<b>A Cash flow from operating activities</b>		
Profit Before Tax And Extraordinary Items	98.99	2,054.71
<b>Adjustments for</b>		
Depreciation and amortisation	32.50	31.76
(Profit) / Loss on sale of Property, Plant and Equipments	0.34	-
(Profit) / Loss on sale of Investments (including fair value change)	(49.30)	(9.06)
Finance cost	35.09	44.12
Discount given / (received)	0.04	4.47
Dividend on investments	(1.42)	(0.80)
Interest income	(10.56)	(2.36)
<b>Operating cash flow before working capital changes</b>	<b>105.68</b>	<b>2,122.84</b>
<i>Add / (Less): Adjustments for working capital changes</i>		
(Increase) / Decrease in Trade Receivables	(1,852.68)	(1,017.03)
(Increase) / Decrease in Other Financial Assets	0.80	(225.10)
(Increase) / Decrease in Other non financial assets	105.74	(85.38)
(Increase) / Decrease in inventories	1,258.01	(2,140.27)
Increase / (Decrease) in Other bank balances	-	-
Increase / (Decrease) in Trade payables	(664.01)	(830.89)
Increase / (Decrease) in Other financial liabilities	97.14	(84.95)
Increase / (Decrease) in Other non-financial liabilities	-	-
Increase / (Decrease) in Provisions	-	5.02
<b>Cash used in operations</b>	<b>(949.32)</b>	<b>(2,255.76)</b>
Income taxes paid Income taxes paid (Net of Refunds Received)	(279.91)	(672.14)
<b>Net cash used in operating activities -A</b>	<b>(1,229.23)</b>	<b>(2,927.90)</b>
<b>B Cash flow from investing activities</b>		
Purchase of property, plant and equipment / capital work in progress	(51.55)	(16.81)
Sale of property, plant and equipment and intangible assets	3.05	-
Purchase of investments	(40.20)	-
Proceeds from sale of investments	53.80	(179.11)
Dividend income	1.42	0.80
Interest income	10.56	2.36
<b>Net cash generated from / (used in) investing activities - B</b>	<b>(22.92)</b>	<b>(192.76)</b>
<b>C Cash flow from financing activities</b>		
Interest and finance charges paid	(35.09)	(44.12)
Payment of dividend	(30.90)	-
Loan taken / (Repayment) Long Term Borrowings	-	683.58
Proceeds / Repayment - Short Term Borrowings	136.86	1,427.56
<b>Net cash generated from financing activities - C</b>	<b>70.87</b>	<b>2,067.02</b>
<b>Net increase / (Decrease) in cash and cash equivalents (A+B+C)</b>	<b>(1,181.28)</b>	<b>(1,053.64)</b>
Cash and cash equivalent as at the beginning of the year	1,186.21	1,470.50
Cash and cash equivalent as at the end of the year	4.93	416.86

For Samrat Pharmachem Limited



*[Signature]*  
Director





# Shah & Savla LLP

## Chartered Accountants

CA Mulesh Savla  
Advisory & Regulatory

CA Nilesh Dedhia  
Direct Tax & Litigation

CA Miral Nagda  
Audit & Assurance

CA Nihar Dharod  
Indirect Tax & Litigation

### Independent Auditor's Review Report on Quarterly and Year-to-date Unaudited Financial Results of the Company pursuant to the regulation 33 of SEBI (Listing obligations and Disclosure Requirements) Regulation, 2015, as amended

#### To the Board of Directors of Samrat Pharmachem Limited

1. We have reviewed the accompanying statement of unaudited financials result of Samrat Pharmachem Limited, for the Quarter ended 30<sup>th</sup> September, 2023 and year to date results for the period from 01 April 2023 to 30 September 2023 (the "statement") attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, as amended.
2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors / Committee of Board of Directors has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim financial information performed by Independent Auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement is free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with standards on auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Shah & Savla LLP  
Chartered Accountants  
Firm Reg: No.:109364W/W100143

CA. Mulesh M. Savla  
(Partner)  
Membership No. 038404



UDIN: 23038404 BG ZHRX 7028  
Place: Mumbai  
Date: 8<sup>th</sup> November, 2023